Treatment of Hyponatremia in SIADH
Fluid restriction to 1 L/day is the first-line treatment for asymptomatic or mild SIADH-induced hyponatremia, while hypertonic 3% saline is reserved for severe symptomatic cases with careful monitoring to prevent osmotic demyelination syndrome. 1, 2, 3
Diagnosis of SIADH
SIADH is characterized by:
- Hyponatremia (serum sodium < 134 mEq/L) 1
- Hypoosmolality (plasma osmolality < 275 mosm/kg) 1
- Inappropriately high urine osmolality (> 500 mosm/kg) 1
- Inappropriately high urinary sodium concentration (> 20 mEq/L) 1
- Absence of hypothyroidism, adrenal insufficiency, or volume depletion 1
Treatment Algorithm Based on Symptom Severity
Severe Symptomatic Hyponatremia (Mental status changes, seizures, coma)
- Administer 3% hypertonic saline with a goal to correct 6 mmol/L over 6 hours or until severe symptoms resolve 2, 3
- Total correction should not exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 2, 3, 4
- Monitor serum sodium every 2 hours initially 2
- Transfer to ICU for close monitoring 2
- Calculate sodium deficit using formula: Desired increase in Na (mEq/L) × (0.5 × ideal body weight in kg) 3
- When severe symptoms resolve, transition to mild/asymptomatic protocol 2
Mild Symptomatic Hyponatremia (Nausea, vomiting, headache) or Na < 120 mEq/L
- Fluid restriction to 1 L/day 1, 2, 3
- Monitor sodium every 4 hours 2
- If no response to fluid restriction, add oral sodium chloride 100 mEq three times daily 2, 3
- Consider high protein diet to increase solute intake 3
Asymptomatic Hyponatremia
- Fluid restriction to 1 L/day 1, 2, 3
- Monitor sodium daily 2
- If no response after 24-48 hours, consider adding oral sodium chloride 100 mEq three times daily 3
Second-Line Treatment Options
If fluid restriction and salt supplementation fail to correct hyponatremia:
Vasopressin receptor antagonists (vaptans):
- Tolvaptan starting at 15 mg once daily, can be increased to 30 mg after 24 hours, maximum 60 mg daily 5
- Must be initiated in hospital setting with close monitoring of serum sodium 5
- Avoid fluid restriction during first 24 hours of therapy 5
- Do not administer for more than 30 days due to risk of liver injury 5
Demeclocycline: Alternative option mentioned in guidelines 1
Urea: Considered effective and safe as second-line therapy 6
Monitoring and Safety Considerations
- For severe hyponatremia correction, limit rate to < 8 mmol/L per 24 hours 2, 3, 4
- For chronic hyponatremia, slower correction is safer to prevent osmotic demyelination syndrome 4
- Patients with malnutrition, alcoholism, or advanced liver disease require more cautious correction rates (4-6 mmol/L per day) 4
- Monitor for signs of overcorrection; be prepared to administer hypotonic fluids if correction occurs too rapidly 6
Common Pitfalls to Avoid
- Overly rapid correction of chronic hyponatremia leading to osmotic demyelination syndrome 4, 7
- Inadequate monitoring during active correction 4
- Using hypertonic saline in non-severe cases 8
- Failing to recognize and treat the underlying cause of SIADH 4
- Using fluid restriction in cerebral salt wasting (which can be confused with SIADH) 4
Special Considerations
- When using tolvaptan, monitor serum sodium at 0,6,24, and 48 hours to prevent overly rapid correction 9
- If tolvaptan is discontinued after more than 5-6 days, monitor for hyponatremic relapse 9
- In clinical trials, tolvaptan was more effective than placebo in increasing serum sodium levels in patients with SIADH 5
- Patients receiving tolvaptan should be advised to continue fluid intake in response to thirst 5